Investigational Foam May Offer Itch Relief for Psoriasis Patients

An investigational aerosol foam may provide rapid itch relief as well as improvements in itch-related sleep loss for patients with psoriasis, according to new data presented at the recent World Congress of Dermatology. According to the Phase 3 clinical trial, 426 psoriasis patients were split into two groups, with 323 patients receiving Enstilar (calcipotriol/betamethasone dipropionate 50 micrograms/g / 0.5 mg/g, LEO Pharma) and 103 patients receiving placebo in the form of the aerosol foam vehicle alone. The investigators found that 37 percent of patients using Enstilar had achieved improvements in itch after three days and 84 percent of patients using Enstilar achieved improvement in itch after four weeks. Similarly, patients using Enstilar experienced improvements in itch-related sleep loss, with 36 percent improving after three days and 71 percent experiencing improvements by week four.